Privia Health CFO Mountcastle sells $116k in shares

Privia EVP & CFO David Mountcastle sold 5,566 shares at $20.85 on April 2, 2026 for roughly $116,051 to cover RSU taxes and now holds 214,847 shares directly plus 8,695 indirectly. Multiple analysts upgraded price targets or reiterated buys after stronger-than-expected Q4 2025 results and 2026 guidance: Piper Sandler raised its PT to $36 (Overweight) and highlighted 38.7% YoY adjusted EBITDA growth for 2025, Jefferies raised its PT to $32 from $30, Truist reiterated Buy at $33, and Citizens maintained Market Outperform at $31. These analyst actions and the beat/guidance upside suggest positive near-term upside for PRVA shares.

Analysis

Analyst enthusiasm and improving adjusted-EBITDA trajectory imply the market is starting to price a durability story for PRVA's value-based care platform rather than a pure primary-care roll-up. If margin expansion is driven by scalable MSSP economics (lower marginal cost per patient and higher upside from reconciliations), a 12–24 month earnings re-rating is plausible as multiple compression from growth uncertainty reverses.

Second-order winners include care-coordination software vendors and downstream specialist groups that capture referral volume; conversely, low-cost urgent-care and fee-for-service incumbents face tighter unit economics as payors shift to total-cost-of-care contracts. However, the MSSP/ACO model is lumpy: timing of reconciliations, patient risk-mix drift, and provider productivity are the levers that can swing quarterly results materially.

Key risks are near-term execution (retention of PCPs, membership growth per market) and macro drivers that affect medical-cost trends and reconciliation payouts; regulatory shifts to risk corridors or changes in Medicare Advantage coding intensity would be immediate reversals. Expect meaningful read-throughs around the next two quarterly results and any public ACO performance disclosures—these are 30–90 day catalysts that can change sentiment quickly.

The consensus is underweighting two things: (1) how quickly fixed-cost leverage in technology and central operations can translate to margin improvement once membership scales, and (2) the binary downside from a single large ACO miss that could unwind sentiment. Positioning should therefore balance directional exposure to a re-rating with protection against a reconciliation-driven drawdown.

Key Decisions for Investors

• Accumulate PRVA equity on weakness with a 6–12 month horizon; position size small-to-medium (3–5% portfolio) and set a tactical stop-loss of 12–15% to protect against ACO reconciliation shocks. Reward scenario: 30–50% upside if margins sustain and multiple re-rates.
• Buy 9–12 month PRVA call options (moderately OTM) and finance by selling 1–3 month calls around upcoming earnings (diagonal/calendar). This gives asymmetric upside capture into 2–4 quarterly confirmations while reducing cost; be prepared to roll short calls if implied volatility spikes.
• If already long, buy 3–6 month protective puts to cap downside through the next two earnings/reconciliation windows; treat protection as insurance priced against a 10–20% potential drawdown from a single large ACO miss.
• Avoid naked short or large outright long until the next two quarters of ACO performance are reported; alternatively, pair long PRVA with a short position in a broad healthcare services ETF to isolate company-specific execution risk while keeping market beta neutral.